← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #833 OF 1,000 MOST-CITED

Homeopathic drugs, assessment of stability

FDA cited this observation 22 times across 20 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs22
BY FISCAL YEAR
FY20254
FY20243
FY20232
FY20221
FY20211
FY20201
FY20192
FY20184
FY20174

How FDA worded it — real examples

There is no written assessment of stability of homeopathic drug products based at least on marketing experience with the drug product to indicate that there is no degradation of the product for the normal or expected period of use.

True Botanica, LLC · Hartland, Wisconsin · Drugs · 2025-08-22

There is no written assessment of stability of homeopathic drug products based at least on testing or examination of the drug product for compatibility of the ingredients.

Dee Cee Laboratories, Inc · White House, Tennessee · Drugs · 2025-08-11

There is no written assessment of stability of homeopathic drug products based at least on testing or examination of the drug product for compatibility of the ingredients and marketing experience with the drug product to indicate that there is no degradation of the product for the normal or expected period of use.

RNA Bio/Pharma Inc · Chelan, Washington · Drugs · 2025-04-11

There is no written assessment of stability of homeopathic drug products based at least on testing or examination of the drug product for compatibility of the ingredients.

Speciality Pharma Manufacturing, LLC · Carlstadt, New Jersey · Drugs · 2025-04-08

There is no written assessment of stability of homeopathic drug products based at least on testing or examination of the drug product for compatibility of the ingredients.

Puremedy Inc. · Westlake Village, California · Drugs · 2024-07-26

There is no written assessment of stability of homeopathic drug products based at least on testing or examination of the drug product for compatibility of the ingredients.

Puremedy Inc. · Westlake Village, California · Drugs · 2024-02-12

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharma industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →